Biome Australia Ltd · ASX:BIO
Biome Australia — H1 FY26 Earnings Presentation
23 slides from Biome Australia's earnings presentation, Jun 3, 2026
Slide 1: H1 FY26 Results & Company Presentation
Biome Australia H1 FY26 RESULTS & COMPANY PRESENTATION For personal use only Biome Australia Australia’s #1 fastest-growing probiotic brand — clinically-backed, profitable, and scaling. Blair Vega Norfolk · Founder & Managing Director ASX: BIO BIOME AUSTRALIA · ASX: BIO 1
Slide 2: Our mission
For personal use only Biome Australia Group The Microbiome Health Company Our mission To prevent disease, improve health outcomes and quality of life, and make our products accessible to all
Slide 3: Profitable, clinically-differentiated, and scaling
Biome Australia INVESTMENT HIGHLIGHTS Profitable, clinically-differentiated, and scaling For personal use only Biome develops, owns and clinically validates proprietary probiotic strains, sold through pharmacy and practitioner channels under the Activated Probiotics® and Activated Therapeutics® brands
Slide 4: From start-up to Australia's fastest-growing probiotic brand
Biome Australia OUR JOURNEY From start-up to Australia’s fastest-growing probiotic brand For personal use only Revenue has compounded at ~86% a year from FY20 to FY25 — and FY26 has opened with a record half. FY20 FY25 FY26 $830k → $18.4m → Record H1 First full year of sales Revenue, +41.6% — first n
Slide 5: Record results across every key metric
Biome Australia H1 FY26 FINANCIAL SCORECARD Record results across every key metric For personal use only REVENUE ADJUSTED EBITDA NET PROFIT $12.40m $1.47m $1.18m +40% vs PCP 8th consecutive quarter +172% vs PCP GROSS MARGIN OPERATING CASH FLOW EPS 61% $2.09m 0.53c 1H25: 61.0% $3.21m turnaround +165%
Slide 6: Earnings growing far faster than revenue
Biome Australia OPERATING LEVERAGE Earnings growing far faster than revenue For personal use only +40% +172% Revenue growth (PCP) Net profit growth (PCP) Profit is compounding more than four times faster than revenue — with gross margin held at 61.1% and an eighth consecutive EBITDA-positive quarter.
Slide 7: Compounding revenue, now profitable
Biome Australia REVENUE TRAJECTORY Compounding revenue, now profitable For personal use only H1 FY26 $12.4m Revenue · +40% PCP $1.47m Adj EBITDA (excl SBP) FY25 — first full-year net profit. Eight straight EBITDA-positive quarters. FY20‒FY25 actual full-year revenue. H1 FY26 actual was $12.4m, up 40% o
Slide 8: Onshoring manufacturing — margin and working-capital upside
Biome Australia MANUFACTURING & MARGIN Onshoring manufacturing — margin and working-capital upside For personal use only A binding supply & purchase agreement brings key manufacturing onshore — structurally lifting gross margin and releasing working capital. Gross-margin uplift Working-capital relea
Slide 9: A large market — significant growth headroom
Biome Australia MARKET OPPORTUNITY A large market — significant growth headroom For personal use only Global probiotics market ~US$75bn+ growing 7‒9% p.a. Australian probiotics market ~A$600m ← significant headroom Biome today ~$25m* We hold a low-single-digit share of our home market today — with 8,0
Slide 10: Fastest-growing brand in pharmacy's biggest category
Biome Australia MARKET POSITION Fastest-growing brand in pharmacy’s biggest category For personal use only Largest probiotic brand in community pharmacy #1 Community pharmacy (ex CW) by revenue — and the fastest growing. #2 Terry White Chemmart Second-largest brand by revenue in largest category. Mo
Slide 11: Practitioner endorsement drives full-margin growth
Biome Australia HOW WE WIN Practitioner Only - High Value - Solution driven For personal use only Practitioner endorsement drives full-margin growth 1 2 3 4 5 → → → → Practitioner Clinical Pharmacy purchase Scan data validates Category leadership education recommendation A pull model. Demand is crea
Slide 12: Two clinically-backed brand families
Biome Australia PRODUCT PLATFORM Two clinically-backed brand families For personal use only Activated Probiotics® Activated Therapeutics® Condition-specific, practitioner-recommended Selective, clinically-validated formulations probiotics across the range. for targeted applications. BIOME AUSTRALIA ·
Slide 13: Adjunct medication opportunities
Biome Australia MARKET EXPANSION Adjunct medication opportunities For personal use only Condition-specific range enables multiple products per patient, positioned alongside medical treatment. ATC MEDICATION CATEGORY VOLUME (FY21) ACTIVATED PROBIOTICS PRODUCT & ADJUNCT USE 10M To help restore the bala
Slide 14: The clinical moat competitors can't replicate
Biome Australia CLINICAL EVIDENCE The clinical moat competitors can’t replicate For personal use only • 30+ randomised controlled trials on Biome’s finished products. • Peer-reviewed publication, including in The Lancet. • Evidence across mood & sleep, immune & respiratory, skin, bone, cholesterol an
Slide 15: A proprietary strain in human clinical trial
Biome Australia LEAD ASSET — BMB18 A proprietary strain in human clinical trial For personal use only BMB18 — Lactiplantibacillus plantarum · 100% Biome-owned · DSM registered • In-vitro results: immune modulation, oxidative-stress reduction, gut-barrier integrity. • 240-participant, double-blind, p
Slide 16: From 100 stores to a 7,500-store footprint
Biome Australia DISTRIBUTION From 100 to a 7,500-store footprint For personal use only ~7,500 ~12,000 8,000 Points of sale by end FY26 Addressable AU locations FY27 target (Vision 27) Progress to the Vision 27 distribution target Started at 100 stores 8,000 by FY27 Distribution has grown from 100 to
Slide 17: International: five markets live
Biome Australia INTERNATIONAL Five markets live; international sales up 69% in FY25 with careful investments in FY26 to build the foundation with low run rate For personal use only AUSTRALIA CANADA IRELAND & UK NEW ZEALAND Established Growing Launched Launched Scaled domestic base Fullscript live al
Slide 18: The roadmap to FY27
Biome Australia VISION 2027 The roadmap to FY27 For personal use only FY25 FY26 FY27 DELIVERED IN PROGRESS TARGET • First net profit ($214,656) • H1 revenue $12.4m, +40% PCP • $75m cumulative sales (FY25‒FY27) • Revenue $18.4m, +41.6% • 8th consecutive EBITDA+ quarter • 8,000 points of sale • Interna
Slide 19: Near-term value drivers
Biome Australia H2 OUTLOOK & CATALYSTS Near-term value drivers For personal use only Winter immunity campaign International momentum Major above-the-line activation — outdoor, digital and Canada scaling with Fullscript; Ireland, UK and New Zealand co-branded with key retail partners — timed to peak
Slide 20: Why Biome
Biome Australia INVESTMENT CASE Why Biome For personal use only Category leader Premium-margin model #1 fastest-growing probiotic brand in 61% gross margin, sustained Australia’s biggest pharmacy category. without promotional discounting. Operating leverage proven Proprietary IP pipeline First net p
Slide 21: Capital structure: snapshot & balance sheet
Biome Australia CAPITAL STRUCTURE Snapshot & balance sheet For personal use only ASX code BIO BALANCE SHEET Share price 22.5c Net cash position, no dilution overhang Market capitalisation $51.5m $3.39m cash against $2.12m drawn — with a further $2.89m undrawn and no options or performance rights on
Slide 22: Thank you
Biome Australia THANK YOU For personal use only Profitable. Clinical. Scaling. Blair Vega Norfolk · Founder & Managing Director Lauren Dwyer · Chief Financial Officer corporate@biomeaustralia.com biomeaustralia.com · activatedprobiotics.com.au ASX: BIO Certified B Corporation. BIOME AUSTRALIA · ASX: BIO
Slide 23: Disclaimer
Biome Australia DISCLAIMER This presentation and the information contained within it (the “information”) has This presentation contains forward-looking statements, which may be identified by The recipient must, and agrees with the Company that it will, make its own been prepared solely for the use an